Bristol Myers (BMY -0.6%) is lower today after being cut to Market Perform at BMO Capital on the...
Bristol Myers (BMY -0.6%) is lower today after being cut to Market Perform at BMO Capital on the back of strong competitive Hep-C data from competitor Gilead (GILD +11.5%) and Merck's (MRK +0.3%) anti-PD-1 cancer immunotherpy results.
From other sites
Bristol Myers Squibb : OPINION: From the Editor: Fill Your Bucket List Foundation grants wishes to adult cancer patientsat 4-traders.com (Mar 24, 2015)
at Benzinga.com (Feb 26, 2015)
at Benzinga.com (Feb 25, 2015)
at CNBC.com (Feb 17, 2015)
at Investor's Business Daily (Jan 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs